

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Badimon Lina	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Burson Masteller : Nutrition (2017) - Astra Zeneca : Thrombosis (2017) - Sanofi Aventis : Lipids (2017-2018) - Astra Zeneca : Diabetes (2018) - Pfizer : Diabetes (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astrazeneca : Thrombosis (2017-2018)
Baigent Colin	<p>1- Financial Declaration</p> <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Empagliflozin (2017-2018) - Novartis : Sacubitril (2017-2018) - Pfizer : Sirolimus (2017-2018)
Casula Manuela	<p>Nothing to be declared (2017-2018)</p>
Catapano Alberico	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astra Zeneca : Cardiovascular (2017)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Catapano Alberico	<ul style="list-style-type: none"> - Kowa : Cardiovascular (2017) - Pfizer : Cardiovascular (2017-2018) - Sanofi Aventis : Cardiovascular (2017-2018) - Amgen Inc : Cardiovascular (2017-2018) - Merck Sharp & Dohme : Cardiovascular (2017-2018) - Recordati International : Cardiovascular (2017-2018) - Aegerion : Cardiovascular (2017-2018) - Esperion : cardiovascular (2017-2018) - Mylan : cardiovascular (2017-2018) - Ackcea : Cardiovascular (2017-2018) - Doc Generici : cardiovascular (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Merck Sharp & Dohme : Cardiovascular (2017) - Amgen : cardiovascular (2017-2018) - Pfizer : Cardiovascular (2017-2018) - Sanofi Aventis : Cardiovascular (2017-2018) - Mylan : Cardiovascular (2018) - Doc Generici : Cardiovascular (2018)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Chapman John	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Unilever : human Nutrition and CVD (2017) - Servier : lipid lowering and CVD (2017-2018) - Kowa : lipid lowering and CVD (2017-2018) - MSD : lipid lowering and CVD (2017-2018) - Amgen : PCSK9 inhibition (2017-2018) - Sanofi-Regeneron : PCSK9 inhibition (2017-2018) - Alexion : lysosomal acid lipase deficiency (2018) - Amarin : Triglyceride lowering and CVD (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Pfizer : Diabetic dyslipidemia (2017-2018) - Kowa : Lipid lowering, dyslipidemia and CVD (2017-2018) - Amgen Inc : lipid lowering therapy (2018)
De Backer Guy	<p>Nothing to be declared (2018)</p> <p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott : speaker fee, 2017 (2017)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Delgado Victoria	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott Vascular : Mitraclip (2017-2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boston Scientific : pacemakers (2017) - Medtronic : pacemakers (2017) - Biotronik : pacemakers (2017) - Edwards Lifesciences : valves (2017) - GE Healthcare : Echocardiography (2018) - Edwards Lifesciences : Transcatheter valve interventions (2018)
Ference Brian A	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Sanofi Aventis : Consultant; Advisory Boards; Honoraria (2017-2018) - Regeneron : Consultant; Advisory Boards; Honoraria (2017-2018) - Amgen : Consultant; Advisory Boards; Research Grant; Honoraria (2017-2018) - Merck Sharp & Dohme : Consultant; Advisory Boards; Research Grant; Honoraria (2017-2018) - Medicines Company : Consultant; Honoraria (2017-2018) - Ionis : Consultant; Honoraria (2017-2018) - Esperion Therapeutics : Consultant; Research Grant; Honoraria (2017-2018)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
FERENCE BRIAN A	<ul style="list-style-type: none"> - Novartis : Research Grant (2017-2018) - Eli Lilly : Consultant; Honoraria (2018) - Novo-Nordisk : Consultant; Honoraria (2018) - Krka Pharma : Consultant; Honoraria (2018) - dalCOR Therapeutics : Consultant; Honoraria (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Esperion Therapeutics : LDL; ACL inhibition (2017-2018) - Mckesson Sharp & Dohme : LDL; NPC1L1 inhibition (2017-2018) - Amgen : PCSK9 inhibitors; lipids; Lp(a) (2017-2018) - Novartis : Lp(a); Lp(a) inhibition (2018)
GRAHAM IAN MAKILIM	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Amgen : Advisory Board attendance (2017) - Menarini : Lectures on Prevention and lipid Guidelines only (2017) - Merck Sharp & Dohme : Lectures on Prevention and Lipid Guidelines only (2017) - USB Biopharma : Consultancy on risk estimation- no remuneration thus far (2018) - Merck Sharp & Dohme : Lectures on Prevention and Lipid Guidelines only (2018)
HALLIDAY ALISON	Nothing to be declared (2018)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Halliday Alison	1- Financial Declaration B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Meded Global Solutions : Stroke Prevention and Management Guidelines Forum (2017)
Koskinas Konstantinos	1- Financial Declaration A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Sanofi Aventis : Cardiovascular (2017) - Amgen : Cardiovascular (2017-2018)
Landmesser Ulf	1- Financial Declaration A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Abbott : Advisory Board fees (2017-2018) - Medicines Company : Advisory Board fees (2017-2018) - Amgen : Speaker fees (2017-2018) - Sanofi Aventis : Speaker fees (2017-2018) D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY. - Bayer AG : Research Grant (2017-2018)
Mach Francois	1- Financial Declaration D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY. - Amgen : Lipids (2017)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Mach Francois	<ul style="list-style-type: none"> - Sanofi Aventis : Lipids (2017) - Merck Sharp & Dohme : Lipids (2017) - Sanofi Aventis : Lipid lowering (2018) - Amgen Inc : Lipid lowering (2018) - MSD : Lipid Lowering (2018)
Mihaylova Borislava	<p>1- Financial Declaration</p> <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Merck Sharp & Dohme : Anacetrapib; Ezetimibe plus Simvastatin (2017) - Perspectum Diagnostics : LiverMultiScan, Liver multi-parametric MRI (2017-2018) - Oxford Biomedical Research Centre, UK National Institute for Health Research : Non-specific (2017-2018) - UK National Institute for Health Research : Non-specific (2017-2018) - Diabetes UK : Non-specific; assessing impact of variability in diabetes care in primary care (2017-2018) - Merck Sharp & Dohme : Anacetrapib (2018)
Pedersen Terje Rolf	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Amgen : Cholesterol lowering (2017-2018) - Sanofi Aventis : Cholesterol lowering (2017-2018)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Riccardi Gabriele	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Barilla Center for food and nutrition Foundation : nutrition (2017) - Istituto MaNutrizionale Carapelli : nutrition (2017) - Daiichi Sankyo Europe GmbH : bempoic acid (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Barilla Food Company : cereal foods (2017) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Barilla Food Company : high amylose rusks (2017) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Member of the Scientific Advisory Board of the Barilla Center for Food and Nutrition Foundation and of the Health and Wellbeing Advisory Board of the Barilla Company Member of the Scientific Advisory Board of the Carapelli Nutrition Foundation (2018)
Richter Dimitrios	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Novo-Nordisk : diabetes (2017) - Novartis : hypertension (2017) - Galenica : Lipids (2017) - Teva Pharmaceutical Industries : lipids, hypertension (2017)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Richter Dimitrios	<ul style="list-style-type: none"> - Edwards Lifesciences : aortic stenosis (2017-2018) - Menarini : CAD- hypertension (2017-2018) - Unipharma : hypertension-thrombosis (2017-2018) - Abbott : lipids (2017-2018) - Amgen : lipids (2017-2018) - Sanofi Aventis : Lipids (2017-2018) - Lilly : Lipids (2017-2018) - Unilever : lipids (2017-2018) - Merck Sharp & Dohme : lipids (2017-2018) - Vianex : lipids (2017-2018) - Bayer Healthcare : Thrombosis (2017-2018) - Servier : LIPIDS (2018) - RAFARM : LIPIDS (2018) - ELPEN : LIPIDS-THROMBOSIS (2018) - Leo Pharma : THROMBOSIS (2018) - NovaGEM CYPRUS : THROMBOSIS (2018)
Sabatine Marc	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Amgen : Cardiology / Vascular Disease (2017) - Astra Zeneca : Cardiology / Vascular Disease (2017)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Sabatine Marc	<ul style="list-style-type: none"> - Novartis : Cardiology / Vascular Disease (2017) - Medicines Company : Cardiology / Vascular Disease (2017) - Bristol Myers Squibb : Cardiology / Vascular Disease (2017) - MedImmune : Cardiology / Vascular Disease (2017) - Intarcia : Cardiology / Vascular Disease (2017) - Esperion : Cardiology / Vascular Disease (2017) - Janssen Research and development : Cardiology / Vascular Disease (2017) - CVS Caremark : Cardiology / Vascular Disease (2017) - Merck : Cardiology / Vascular Disease (2017) - Amgen : Cardiovascular (2018) - Medicines Company : Cardiovascular (2018) - MedImmune : Cardiovascular (2018) - Astrazeneca : Cardiovascular (2018) - Bristol-Myers Squibb : Cardiovascular (2018) - CVS Caremark : Cardiovascular (2018) - Merck : Cardiovascular (2018) - Dyrnamix : Cardiovascular (2018) - IFM Therapeutics : Cardiovascular (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Amgen : Cardiology / Vascular Disease (2017) - Astra Zeneca : Cardiology / Vascular Disease (2017)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Sabatine Marc	<ul style="list-style-type: none"> - Daiichi Sankyo : Cardiology / Vascular Disease (2017) - Novartis : Cardiology / Vascular Disease (2017) - Pfizer : Cardiology / Vascular Disease (2017) - GlaxoSmithKline : Cardiology / Vascular Disease (2017) - Medicines Company : Cardiology / Vascular Disease (2017) - POXEL : Cardiology / Vascular Disease (2017) - Eisai : Cardiology / Vascular Disease (2017) - MedImmune : Cardiology / Vascular Disease (2017) - Intarcia : Cardiology / Vascular Disease (2017) - Janssen Research and development : Cardiology / Vascular Disease (2017) - Merck : Cardiology / Vascular Disease (2017) - Takeda : Cardiology / Vascular Disease (2017) - Amgen : Cardiovascular (2018) - Bayer : Cardiovascular (2018) - Novartis : Cardiovascular (2018) - Pfizer : Cardiovascular (2018) - GlaxoSmithKline : Cardiovascular (2018) - Medicines Company : Cardiovascular (2018) - Takeda Pharmaceuticals : Cardiovascular (2018) - Eisai : Cardiovascular (2018) - MedImmune : Cardiovascular (2018)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Sabatine Marc	<ul style="list-style-type: none"> - Astrazeneca : Cardiovascular (2018) - Daiichi-Sankyo : Cardiovascular (2018) - Intarcia : Cardiovascular (2018) - Merck : Cardiovascular (2018) - Quark Pharmaceuticals : Cardiovascular (2018) <p>2- Other Positions of Influence</p> <p>2.2 - Employment in healthcare industry (including part time) during the year for which you are declaring.</p> <ul style="list-style-type: none"> - See above noted employers (2017)
Taskinen Marja-Riitta	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Sanofi Aventis : PCSK9 anti-sense (2017) - Novo-Nordisk : GLP-1 agonist (2017-2018) - Chiesi Pharma : Glybera (2017-2018) - Amgen : PCSK9 anti-sense (2017-2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Novo-Nordisk : GLP1-analogue (2017-2018) - Amgen : PCSK9 anti-sense (2017-2018) - Sanofi Aventis : PCSK9 anti-sense (2017-2018)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Tokgozoglulale	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astra Zeneca : dyslipidemia, hypertension, antiplatelet, pulmonary hypertension (2017) - Pfizer : lipids (2017) - Daiichi Sankyo : antiplatelet (2017-2018) - Sanofi Aventis : antiplatelet, lipid (2017-2018) - Novo-Nordisk : diabetes (2017-2018) - Abbott : dyslipidemia (2017-2018) - Recordati International : dyslipidemia (2017-2018) - Mylan : dyslipidemia (2017-2018) - Novartis : heart failure (2017-2018) - Servier : hypertension (2017-2018) - Amgen : lipid (2017-2018) - Merck Sharp & Dohme : lipid (2017-2018) - Actelion : pulmonary hypertension (2017-2018) - Bayer Healthcare : antiplatelet (2018) - Pfizer : lipids, cardiomyopathy (2018)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Wiklund Olov	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Amgen : Cardiovascular prevention, lipid lowering (2017-2018) - Sanofi Aventis : Cardiovascular prevention, lipid lowering (2017-2018)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Abid Leila	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Sanofi Aventis : aprovasc (2018) - Novartis : exforge (2018) - Abbott : odrik (2018)
Aboyans Victor	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer : Antithrombotic therapy (2018) - BMS/Pfizer Alliance : Antithrombotic therapy (2018) - NovoNordisk : Diabetes (2018) - Novartis : Heart Failure (2018) - Amgen : Lipid lowering therapy (2018) - Sanofi Aventis : PAD (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer Healthcare : PAD (2018)
Agladze Rusudan	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Johnson & Johnson : investigator (2018)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Agladze Rusudan	- Relypsa : Investigator (2018)
Bajnok Laszlo	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Sanofi Aventis : alirocumab (2018) - Amgen : evolocumab (2018) - Merck Sharp & Dohme : ezetimib, statins (2018) - Krka Pharma : ezetimib, statins (2018) - Novo-Nordisk : Norditropin, GH deficiency (2018) - Pfizer : pegvisomant, acromegaly (2018) - Novartis : Sandostatin LAR, acromegaly (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Ipsen : acromegaly, lanreotide (2018) - Novo-Nordisk : Norditropin, GH deficiency (2018)
Bajraktari Gani	Nothing to be declared (2018)
Boskovic Aneta	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Servier : Arterial hypertension (2018)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Boskovic Aneta	- Sanofi Aventis : PTE (2018)
Collet Jean-Philippe	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Apixaban (2018) - Astra Zeneca : TICAGRELOR (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : apixaban (2018) - Medtronic : COREVALVE (2018)
Corsini Alberto	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Amgen : Cardiovascular (2018) - Astra Zeneca : Cardiovascular (2018) - Daiichi Sankyo : Cardiovascular (2018) - Pfizer : Cardiovascular (2018) - Servier : Cardiovascular (2018) - Sanofi Aventis : Cardiovascular (2018) - Bristol Myers Squibb : cardiovascular (2018) - Recordati International : Cardiovascular (2018) - Mylan : Generic (2018)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Corsini Alberto	- DOC : Generic (2018)
Dingli Philip	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <p>- Servier : Single pill combination therapy in hypertension (2018)</p>
Doehner Wolfram	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Medtronic : Ad diagnostica (2018) - Bayer AG : Anticoagulation (2018) - Sphingotec : biomarker (2018) - Sanofi Aventis : cv therapeutics (2018) - Boehringer-Ingelheim : Heart failure (2018) - Vifor International : Iron therapy (2018) - Medscape : medical education (2018) - Pfizer : Stroke prevention (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - ZS Pharma : Cardiovascular therapeutic (2018) - Vifor International : Iron therapy (2018)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Drexel Heinz	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boehringer Ingelheim: lecture honoraria and consulting activity : Diabetes (2018) - NovoNordisk: consulting activity : Diabetes (2018) - Amgen: lecture honoraria : Lipids (2018) - MSD: lecture honoraria : Lipids (2018) - Sanofi-aventis: lecture honoraria and consulting activity : Lipids (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boehringer Ingelheim : Diabetes (2018)
Ezhov Marat	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astra Zeneca : Atherosclerosis (2018) - Pfizer : Atherosclerosis (2018) - Sanofi Aventis : Atherosclerosis (2018) - Berlin Chemie AG : Atherosclerosis (2018) - Amgen Inc : Atherosclerosis (2018) - Egis Pharma : Atherosclerosis (2018) - Recordati International : Atherosclerosis (2018) - Alexion : Atherosclerosis (2018)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Ezhov Marat	<ul style="list-style-type: none"> - Krka Pharma : Atherosclerosis (2018) - Novo-Nordisk : Obesity (2018)
Farnier Michel	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott : Lipid lowering-drug (2018) - Amgen : Lipid lowering-drug (2018) - Astra Zeneca : Lipid lowering-drug (2018) - Daiichi Sankyo : Lipid lowering-drug (2018) - Eli Lilly : Lipid lowering-drug (2018) - Pfizer : Lipid lowering-drug (2018) - Servier : Lipid lowering-drug (2018) - Genzyme : Lipid lowering-drug (2018) - Kowa : Lipid lowering-drug (2018) - Mylan : Lipid lowering-drug (2018) - Akcea/Ionis : Lipid lowering-drug (2018) - Merck and Co : Lipid lowering-drug (2018) - Sanofi/Regeneron : Lipid lowering-drug (2018)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Ferrieres Jean	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Amgen : Lipids (2018) - Servier : Lipids (2018) - Sanofi Aventis : Lipids (2018) - Merck Sharp & Dohme : Lipids (2018) <p>2- Other Positions of Influence</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - Board of the French Society of Cardiology (2018)
Fontes Carvalho Ricardo	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Antidiabetic drugs (2018) - Merck Sharp & Dohme : dyslipidemia (2018) - Novartis : Heart failure (2018) - Bial Portela : Hypertensiom (2018) - Menarini : Hypertension (2018) - Bristol-Meyers Squibb Farmaceutica Portuguesa, SA : NOAC (2018) - Bayer : NOACs (2018) - Daiichi Sankyo : NOACs (2018)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Foscoli Marina	Nothing to be declared (2018)
Fras Zlatko	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer : anticoagulation therapy (2018) - Pfizer : anticoagulation therapy (2018) - Astra Zeneca : antiplatelet therapy (2018) - Boehringer-Ingelheim : cardiometabolism (2018) - Novo-Nordisk : cardiometabolism (2018) - Servier : general cardiology (2018) - Krka Pharma : hypertension, lipids (2018) - Amgen : lipid treatment (2018) - Sanofi Aventis : lipid treatment (2018)
Gaita Dan	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astra Zeneca : Cardiology (2018) - Novartis : Cardiology (2018) - Pfizer : Cardiology (2018) - Servier : Cardiology (2018)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Gaita Dan	<ul style="list-style-type: none"> - Sanofi Aventis : Cardiology (2018) - Terapia : Cardiology (2018) - Mylan : Cardiology (2018) - Novo-Nordisk : Diabetology (2018) <p>2- Other Positions of Influence</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - Romanian Heart Foundation Romanian Forum for CVD Prevention European Heart Network (2018)
Giga Vojislav	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Krka Pharma : Speaker Fees (2018)
Gigante Bruna	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Pfizer : Autoimmune diseases, lecture fee (2018)
Gudjonsson Thorbjorn	<p>2- Other Positions of Influence</p> <p>2.2 - Employment in healthcare industry (including part time) during the year for which you are declaring.</p> <ul style="list-style-type: none"> - Have a part time private office. "Hjartapipulagnir slf". No external funding. (2018)
Gulizia Michele Massimo	<p>Nothing to be declared (2018)</p>

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Hagstrom Emil	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Diabetes (2018) - Novo-Nordisk : diabetes (2018) - Astra Zeneca : Diabetes mellitus, speakers fee (2018) - Sanofi Aventis : Secondary prevention, speakers fee (2018) - Amgen Inc : Secondary prevention, speakers fee (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Dalcor : investigator post-MI treatment (2018)
Hamoui Omar	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astra Zeneca : ACS (2018) - Astra Zeneca : Dyslipidemia (2018) - Novartis : Entresto (2018) - Boehringer-Ingelheim : NOACS (2018) - Pfizer : NOACs (2018) - Astra Zeneca : SGLT2i (2018)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Henkin Yaakov	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Novartis : Entresto (2018) - Boehringer-Ingelheim : Jardiance (2018) - Sanofi Aventis : Praluent (2018) - Amgen : Repatha (2018) - Novo-Nordisk : Victoza (2018)
Ivanov Victoria	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Berlin Menarini : nebivolol (2018) - Krka Pharma : rosuvastatina (2018)
Jankowski Piotr	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Amgen : Hyperlipidaemia (2018) - Servier : Hyperlipidaemia (2018) - Sanofi Aventis : Hyperlipidaemia (2018) - Zentiva : Hyperlipidaemia (2018) - Berlin Chemie AG : Hypertension (2018)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Jankowski Piotr	<p>- Krka Pharma : Hypertension (2018)</p> <p>E - RESEARCH FUNDING (PERSONAL).</p> <p>- Sanofi Aventis : Hyperlipidaemia (2018)</p>
Kayikcioglu Meral	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <p>- Pfizer : AMILOIDOSIS (2018)</p> <p>- Abbott : fenofibrate (2018)</p> <p>- Recordati International : PITAVASTATIN (2018)</p> <p>- Sanofi Aventis : SanofiCARDOIVASCULAR (2018)</p> <p>2- Other Positions of Influence</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <p>- FH-EUROPE (familial hypercholesterolemia PATIENT ASSOCIATION of Both EUROPE and TURKEY 2018)</p>
Kerimkulova Alina	<p>Nothing to be declared (2018)</p>
Krstacic Goran	<p>Nothing to be declared (2018)</p>
Kypris Lambros	<p>Nothing to be declared (2018)</p>
Lambrinou Ekaterini	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <p>- Health Policy Partnership : HF Policy Network Handbook Launch (2018)</p>

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Lambrinou Ekaterini	<ul style="list-style-type: none"> - Bayer AG : Honorarium (2018) - TRAMA SOLUTIONS : Online course speaker fees (2018) - Novartis : Speaker fee and honorarium (2018)
Larsen Mogens Lytken	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astra Zeneca : farmaka (speakers honorarium) (2018) - Boehringer-Ingelheim : Farmaka (speakers honorarium) (2018) - Sanofi Aventis : Farmaka (speakers honorarium) (2018)
Latkovskis Gustavs	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer : Anticoagulants (2018) - Boehringer-Ingelheim : Anticoagulants (2018) - Berlin Chemie AG : Antihypertensive agents (2018) - Sanofi Aventis : Antihypertensive therapies, risk estimation and management, prevention (2018) - Menarini : Antihypertensive therapy (2018) - Abbott Laboratories : Cardiac markers (2018) - Novo-Nordisk : Cardiovascular risk and diabetes (2018) - University of Latvia : Education (2018) - Novartis : Heart failure (2018)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Latkovskis Gustavs	<ul style="list-style-type: none"> - Servier : Hypertension, heart rate, lipid lowering, risk reduction (2018) - Mylan : Lipid lowering therapies (2018) - Astra Zeneca : lipid-lowering drugs, anti platelets (2018) - Krka Pharma : Lipid-lowering therapies (2018) - Amgen : Lipid-lowering. (2018) - Siemens Healthcare : Myocardial damage markers (2018) - Roche Diagnostics : Myocardial damage markers (2018) - Riga Stradins University : Postgraduate education (2018) - Latvian Institute of Cardiology and Regenerative Medicine : Primary hyperlipidemias, genetics of CVD (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Latvian Council of Science : Trimethylamine N-oxide and glucose metabolism; familial hypercholesterolemia. (2018) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Latvian Medical Association, board member and chairman of the Certification Council Baltic Atherosclerosis Society, board member Latvian Society of Cardiology, board member The University of Latvia, Faculty of Medicine, vice-dean (2018)
Laufs Ulrich	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Amgen : ASCVD (2018) - Bayer : ASCVD (2018) - Boehringer-Ingelheim : ASCVD (2018) - Novartis : ASCVD (2018)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Laufs Ulrich	<ul style="list-style-type: none"> - Sanofi Aventis : ASCVD (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Amgen : ASCVD (2018) - Sanofi Aventis : ASCVD (2018)
Lehmann Roger	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Amgen : Diabetes (2018) - Boehringer-Ingelheim : Diabetes (2018) - Eli Lilly : Diabetes (2018) - Sanofi Aventis : Diabetes (2018) - Merck Sharp & Dohme : Diabetes (2018) - Novo-Nordisk : Diabetes (2018)
Lewis Basil S	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Pfizer : Antithrombotics (2018) - Astra Zeneca : Diabetes (2018) - Merck Sharp & Dohme : Heart failure (2018) - CSL Behring : Lipidology, Secondary prevention (2018)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Lewis Basil S	<p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astrazeneca : Antithrombotics (2018) - Astra Zeneca : Diabetes (2018) - Pfizer : Diabetes (2018) - Merck Sharp & Dohme : Heart failure (2018) - Kowa : Lipidology (2018) - Resverlogix : Lipidology. secondary prevention (2018)
Maher Vincent	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Servier : Hypertension (2018) - Amgen : Lipid lowering lecture (2018) - Merck Sharp & Dohme : Lipid lowering lecture (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Sanofi Aventis : National Advanced Lipid Management and Research Centre Development Seed funding for 3 years Salary replacement support to Hospital for secondment so as I can devote the necessary time to develop this national project. (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Amgen : lipid lowering (2018)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Masip Josep	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Menarini : Travel Grant (2018)</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - BRAHMS GmbH : Consultant, Biomarkers (2018) - Mylan : Speaker fee, dislipidemia (2018)</p>
Mbarek Nazi	Nothing to be declared (2018)
Mitchenko Olena	Nothing to be declared (2018)
Moulin Philippe	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - MSD : hypolipidemic drug (2018) - Novo Nordisk : hypolipidemic drug (2018) - Akcea : hypolipidemic drug (2018)</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Boehringer-Ingelheim : antidiabetic agent (2018) - Sanofi Aventis : hypolipidemic drug (2018)</p>

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Moulin Philippe	<ul style="list-style-type: none"> - MSD : hypolipidemic drug (2018) - Akcea : hypolipidemic drug (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Akcea : hypolipidemic drug (2018)
Mueller Christian Eugen	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Antidiabetics (2018) - Indorsia : Antiplatelet therapy (2018) - Roche Diagnostics : Diagnostics (2018) - Sanofi Aventis : Lipid lowering (2018) - Amgen : Lipid-lowering (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Beckman Coulter : Diagnostics (2018) - OrthoClinical Diagnostics : Diagnostics (2018) - Singulex : Diagnostics (2018) - Abbott Laboratories : Diagnostics (2018) - Roche Diagnostics : Diagnostics (2018) - Siemens : Diagnostics (2018) - Sphingotec : Diagnostics (2018) - quidel : Diagnostics (2018)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Mussagaliev Aisulu	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Servier : Stable angina (2018)</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Servier : Stable angina (2018)</p>
Najafov Ruslan	Nothing to be declared (2018)
Nibouche Djamaledine	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Sanofi Aventis : Cardiovascular (2018) - Amgen Inc : Cardiovascular (2018)</p> <p>2- Other Positions of Influence</p> <p>2.1 - Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: To reduce the burden of cardiovascular disease. - Media - N/A no Direct financial interest, services are provided for free Education - Continued Medical Education for cardiologist sponsored by pharma company (2018)</p>
Ozdogan Oner	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Astra Zeneca : Brilinta (2018)</p>

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Ozdogan Oner	<ul style="list-style-type: none"> - Servier : Coversyl, Triplixam, Coralan, Vastarel (2018) - Pfizer : Eliquis (2018) - Abbott : Lipanthyl (2018) - Daiichi Sankyo : Lixiana (2018) - Sanofi Aventis : Plavix (2018) - Boehringer-Ingelheim : Pradaxa (2018) - Menarini : Vasoxen, Latixa, Zoprotec (2018)
Patel Riyaz	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Amgen : Cholesterol management (2018) - Sanofi Aventis : Cholesterol management (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Akcea : Triglyceride lowering (2018) <p>2- Other Positions of Influence</p> <p>2.2 - Employment in healthcare industry (including part time) during the year for which you are declaring.</p> <ul style="list-style-type: none"> - Long term honorary appointments at Barts Health and UCLH NHS trusts (2018)
Pella Daniel	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Amgen : dyslipidemia (2018)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Pella Daniel	<ul style="list-style-type: none"> - Sanofi Aventis : dyslipidemia (2018) - Merck Sharp & Dohme : dyslipidemia (2018) - Servier : dyslipidemia, coronary artery disease, arterial hypertension (2018)
Peovska Mitevaska Irena	Nothing to be declared (2018)
Perez De Isla Leopoldo	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Amgen : Lipids (2018) - Servier : Lipids (2018) - Sanofi Aventis : Lipids (2018) - Esteve : Lipids (2018) - Recordati International : Lipids (2018) - MSD : Lipids (2018) - Mylan : Lipids (2018) - Laboratorios Rubió : Lipids (2018) - Astra Zeneca : Lipids and diabetes (2018)
Petersen Steffen Erhard	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Circle Cardiovascular Imaging, Inc : Cardiac MRI and CT analysis and reporting software (2018)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Petersen Steffen Erhard	<p>- Servier : Heart failure (2018)</p> <p>2- Other Positions of Influence</p> <p>2.1 - Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: To reduce the burden of cardiovascular disease.</p> <p>- Healthcare - IMAGING - I have option for shares for Circle Cardiovascular Imaging Inc. (2018)</p>
Petronio Anna Sonia	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <p>- Boston Scientific : Percutaneous Aortic and Mitral treatment (2018)</p> <p>- Medtronic : Percutaneous Aortic and mitral treatment (2018)</p> <p>- Abbott : Percutaneous Mitral treatment (2018)</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <p>- Boston Scientific : TAVI research (2018)</p>
Piepoli Massimo Francesco	<p>Nothing to be declared (2018)</p>
Pinto Xavier	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <p>- Sanofi Aventis : Alirocumab (2018)</p> <p>- Rubió : Cholestyramine/ NMR of lipoproteins (Liposcale) (2018)</p> <p>- Amgen Inc : Evolocumab (2018)</p>

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Pinto Xavier	<ul style="list-style-type: none"> - Merck Sharp & Dohme : Ezetimibe (2018) - Ferrer Internacional : Omega-3 FA (Omacor) (2018) - Esteve : Pitavastatin (2018) - Mylan : Rosuvastatin-Ezetimibe/ Fenofibrate-Pravastatin (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astra Zeneca : Dapagliflozin (2018)
Pojskic Belma	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Sanofi Aventis : alirocumab (2018) - Krka Pharma : rosuvastatin (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Sanofi Aventis : alirocumab (2018)
Postadzhiyan Arman	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astra Zeneca : ACS (2018) - Bayer : AF (2018) - Boehringer-Ingelheim : AF (2018) - Pfizer : AF, dyslipidemia (2018)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Postadzhiyan Arman	<ul style="list-style-type: none"> - Amgen : dyslipidemia (2018) - Sanofi Aventis : dyslipidemia (2018)
Raber Lorenz	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Sanofi Aventis : Alirocumab (2018) - Amgen : Evolocumab (2018) - Abbott Vascular : OCT (2018) - Bayer : Rivaroxaban (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - CSL Behring : research compound (2018) - Astra Zeneca : Ticagrelor (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Sanofi Aventis : Alirocumab (2018) - HeartFlow : FFR CT (2018) - Abbott Vascular : OCT, FFR (2018)
Rallidis Loukianos	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Amgen : Hypolipidemic treatment (2018)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Rallidis Loukianos	- Sanofi Aventis : Hypolipidemic treatment (2018)
Ray Kausik K	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Novo Nordisk : Diabetes (2018) - Boehringer Ingelheim : Diabetes (2018) - Astra Zeneca : Diabetes Antiplatelets (2018) - Resverlogix : epigenetics (2018) - Amgen : lipids (2018) - Daiichi Sankyo : Lipids (2018) - Medicines Company : Lipids (2018) - Kowa : lipids (2018) - MSD : lipids (2018) - Regeneron : Lipids (2018) - Esperion : lipids (2018) - Akcea : Lipids (2018) - Zuelling Pharma : Lipids (2018) - Dr Reddys : Lipids (2018) - Sanofi Aventis : lipids and Diabetes (2018) - Pfizer : lipids Hypertension (2018) - AbbiVie : Nephrology (2018)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Ray Kausik K	<p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Pfizer : lipids (2018) - Sanofi Aventis : lipids (2018) - Amgen Inc : lipids (2018) - MSD : Lipids (2018) - Regeneron : lipids (2018)
Reiner Zeljko	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Sanofi Aventis : antilipemic drugs (2018)
Retterstol Kjetil	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Sunovion : Dyslipidemia (2018) - Mills DA : Food Industry (2018) - Akcea : Hypertriglyceridemia (2018) - Sanofi Aventis : Praluent (2018) - Amgen : Repatha (2018)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Riesen Walter	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Amgen : Evolocumab (2018)</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Sanofi Aventis : Alirocumab (2018)</p>
Roffi Marco	<p>1- Financial Declaration</p> <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY. - Boston Scientific : Stents (2018) - Medtronic : Stents (2018) - Biotronik : stents (2018) - Terumo Inc : stents (2018) - Abbott Vascular : stents (2018)</p>
Salaheldin Hesham	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Bayer : Anticoagulation (2018) - Novo-Nordisk : DM (2018) - Boehringer-Ingelheim : DM Anticoagulation (2018) - Merck Sharp & Dohme : DM Dyslipidemia (2018)</p>

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Salaheldin Hesham	<ul style="list-style-type: none"> - Servier : Hypertension (2018) - Pfizer : Hypertension & Dyslipidemia (2018) - Novartis : Hypertension & Heart Failure (2018) - Merck Serono : Hypertension CAD (2018) - Abbott : Hypertension Dyslipidemia (2018) - Astra Zeneca : Hypertension, Dyslipidemia & DM (2018) <p>E - RESEARCH FUNDING (PERSONAL).</p> <ul style="list-style-type: none"> - Garefield VTE International Study : Venous thromboembolism (2018)
Schmid Jean-Paul	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Oral antidiabetics (2018) - Sanofi Aventis : PCSK-9 (2018) - Amgen : PCSK-9 inhibition (2018)
Shlyakhto Evgeny	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Krka Pharma : Arterial Hypertension (2018) - Novartis : Arterial Hypertension, Heart Failure (2018) - Merck Sharp & Dohme : Atherosclerosis (2018) - Boehringer-Ingelheim : Dabigatran for Atrial Fibrillation (2018)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Shlyakhto Evgeny	- Pfizer : General Cardiology (2018)
Simpson Iain A	Nothing to be declared (2018)
Siostrzonek Peter	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astra Zeneca : ACS, Diabetes (2018) - Boehringer-Ingelheim : Anticoagulation, Diabetes (2018) - Servier : Hypertension (2018) - Sanofi Aventis : Lipid (2018) - Amgen : Lipid therapy (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Diabetes, anticoagulation (2018)
Slapikas Rimvydas	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Speakers fee from AMGEN, SERVIER, BERLIN CHEMIE, KRKA, BOEHRINGER INGELHEIM, INVESTIGATOR IN 4 CLINICAL TRIALS : hypertension, dyslipidaemia (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Amgen : dyslipidaemia (2018)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Spinar Jindrich	Nothing to be declared (2018)
Strandberg Timo	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Sanofi Aventis : Diabetes (2018) - Merck Sharp & Dohme : Diabetes (2018) - Novo-Nordisk : Diabetes (2018) - Amgen Inc : Dyslipidemia (2018) - Orion : Dyslipidemia, geriatrics, hypertension (2018) - Servier : HYPertension, dyslipidemia (2018) <p>2- Other Positions of Influence</p> <p>2.1 - Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: To reduce the burden of cardiovascular disease.</p> <ul style="list-style-type: none"> - Healthcare - CARDIOVASCULAR PHARMACOLOGY - Minor amount of stock in a listed Company (Helsinki Stock Exchange) OrionPharma (2018)
Stroes Erik	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Akcea-Ionis : antisense therapies (apoCIII, apo(a) (2018) - Novartis : apo(a) siRNA (2018) - Amgen Inc : PCSK0 antibodies, Lp(a) siRNA (2018)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Stroes Erik	<ul style="list-style-type: none"> - Sanofi- Regeneron : PCSK9-antibody (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Sanofi Aventis : PCSK9-ab (2018) - Amgen Inc : PCSK9-ab (2018) <p>E - RESEARCH FUNDING (PERSONAL).</p> <ul style="list-style-type: none"> - Resverlogix : RVX-208 (2018)
Sudano Isabella	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Menarini : Hypertension (2018) - Servier : Hypertension/Lipid (2018) - Amgen : Lipid (2018) - Sanofi Aventis : Lipid (2018) - Merck Sharp & Dohme : Lipid (2018) - Recordati International : Lipid (2018) <p>E - RESEARCH FUNDING (PERSONAL).</p> <ul style="list-style-type: none"> - Swiss Heart Foundation : no therapeutical area Research project on endothelial function (2018)
Tselepis Alexandros	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Amarin : Hypolipidemic drugs (2018)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Tselepis Alexandros	<p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Galenica SA : Antiplatelets (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Lybitec : Antiplateles (2018) - Astra Zeneca : Antiplatelets (2018) - ELPEN : Hypolipidemic drugs (2018)
van de Borne Philippe	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : CV prevention diabetes (2018) - Novo-Nordisk : CV prevention-diabetes (2018) - Amgen : Hypercholestérolémie (2018) - Sanofi Aventis : Hypercholestérolémie (2018) - Menarini : Hypertension (2018) - Merck Sharp & Dohme : Hypertension (2018) - Servier : Hypertensuion (2018)
Viigimaa Margus	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Coagulation (2018) - Astra Zeneca : Diabetes (2018)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Viigimaa Margus	<ul style="list-style-type: none"> - Novo-Nordisk : Diabetes (2018) - Menarini : Hypertension (2018) - Amgen Inc : Lipids (2018) - Sanofi Aventis : Lipids, hypertension (2018)
Vindis Cecile	Nothing to be declared (2018)
Visser Laurent	Nothing to be declared (2018)
Visseren Frank	Nothing to be declared (2018)
Vonbank Alexander	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astra Zeneca : Diabetes (2018) - Boehringer-Ingelheim : Diabetes (2018) - Lilly : Diabetes (2018) - Novo-Nordisk : Diabetes (2018) - Sanofi Aventis : Diabetes, Lipids (2018) - Amgen : Osteoporosis (2018)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Vrablik Michal	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Mylan : lipid metabolism (2018) - Amgen : lipid metabolism, CVD prevention (2018) - Servier : lipid metabolism, CVD prevention (2018) - Sanofi Aventis : lipid metabolism, CVD prevention (2018) - Merck Sharp & Dohme : lipid metabolism, CVD prevention (2018) - Krka Pharma : lipid metabolism, preventive cardiology (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Pfizer : cardiovascular (2018) - Sanofi Aventis : lipid metabolism (2018)
Vrsalovic Mislav	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : speaker fee (2018) - Sanofi Aventis : speaker fee (2018) - Bayer : SPEAKER FEE, ADVISORY BOARD FEE (2018)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Zamorano Gomez Jose Luis	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Anticoagulation Afib (2018) - Amgen : lipids (2018)
Zelveian Parounak	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Takeda Pharmaceuticals : Hypertension (2018) - Egis Pharma : Hypertension & IHD (2018) - Recordati International : Hypertension & IHD (2018) - Krka Pharma : Hypertension & IHD (2018) - Grindex Pharma : Hypertension & IHD (2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Aboyans Victor	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Amgen : Hyperlipidemia (2017) - Novartis : Hypertension (2017) - Boehringer-Ingelheim : Oral anticoagulation (2017) - Bayer Healthcare : Oral anticoagulation (2017) - Pfizer/BMS alliance : Oral anticoagulation (2017) - Bayer : Antithrombotic therapy (2018) - BMS/Pfizer Alliance : Antithrombotic therapy (2018) - NovoNordisk : Diabetes (2018) - Novartis : Heart Failure (2018) - Amgen : Lipid lowering therapy (2018) - Sanofi Aventis : PAD (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer Healthcare : PAD (2018)
Baigent Colin	<p>1- Financial Declaration</p> <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Empagliflozin (2017-2018) - Novartis : Sacubitril (2017-2018) - Pfizer : Sirolimus (2017-2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Collet Jean-Philippe	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Lecture fees representing 2000 euros for 2017. (2017) - Roche Diagnostics : Lecture fees representing 800 euros for 2017. (2017) - Bayer Healthcare : Speaker Fees for antiplatelet therapy. This represented 2000 euros in total for 2017. (2017) - Servier : SPEAKER FEES OF 1000 EUROS IN 2017 (2017) - Bristol Myers Squibb : Apixaban (2018) - Astra Zeneca : TICAGRELOR (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boston Scientific : ACADEMIC RESEARCH DONATION TO THE ACTION FOUNDATION (www.action-fonds.org) (2017) - Bayer AG : ACADEMIC RESEARCH FUNDINGS (ADRIFT TRIALS) to the action study group (www.action-fonds.org) (2017) - Astra Zeneca : ACADEMIC RESEARCH FUNDINGS (ALPHEUS TRIAL) to the action study group (www.action-fonds.org) (2017) - Medtronic : Research fundings for Academic studies (atlantis trial) to the action study group (www.action-coeur.org) (2017) - Bristol Myers Squibb and Pfizer : Research fundings for Academic studies (atlantis trial) to the action study group (www.action-coeur.org) (2017) - Bristol Myers Squibb : apixaban (2018) - Medtronic : COREVALVE (2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Delgado Victoria	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott Vascular : Mitraclip (2017-2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boston Scientific : pacemakers (2017) - Medtronic : pacemakers (2017) - Biotronik : pacemakers (2017) - Edwards Lifesciences : valves (2017) - GE Healthcare : Echocardiography (2018) - Edwards Lifesciences : Transcatheter valve interventions (2018)
Fitzsimons Donna	<p>Nothing to be declared (2017)</p> <p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Medscape : Heart failure (2018)
Gale Christopher Peter	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astrazeneca : ACS, heart failure (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Gale Christopher Peter	<ul style="list-style-type: none"> - Vifor Pharma : Heart failure (2017) - Novartis : heart failure, CVD (2017) - Astra Zeneca : ACS (2018) - Novartis : coronary artery disease (2018) - Bayer : coronary artery disease, AF (2018) - Vifor International : heart failure (2018) - Menarini : ischaemic heart disease (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Apixiban, AF (2018)
Grobbee Diederick E	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Amgen : advisory board (2018) - Esperion : Steering ctt (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Esperion : clinical trial lipids (2018) <p>2- Other Positions of Influence</p> <p>2.2 - Employment in healthcare industry (including part time) during the year for which you are declaring.</p> <ul style="list-style-type: none"> - chief scientific officer Julius Clinical Research Ltd (2017) - chief scientific officer Julius Clinical Research Ltd (part-time) (2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Halvorsen Sigrun	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Antithrombotic treatment (2017-2018) - Astra Zeneca : Anti-thrombotic treatment (2017-2018) - Boehringer-Ingelheim : Anti-thrombotic treatment (2017-2018) - Pfizer : Anti-thrombotic treatment (2017-2018) - Bayer AS : Anti-thrombotic treatment (2017-2018) - Sanofi Aventis : Cholesterol lowering treatment (2017-2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Novartis : Heart failure (2017-2018)
Hindricks Gerhard	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott : Pacemaker, Ablation (2017-2018) - Biosense Webster : Pacemaker, Ablation (2017-2018) - Biotronik : Pacemaker, catheter (2017-2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott, Biotronik, Medtronic, Boston Scientific : Electrophysiology, arrhythmias (2017) - Biosense Webster : Electrophysiology, arrhythmias (2018) - Abbott : Electrophysiology, arrhythmias (2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Hindricks Gerhard	<p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - The Heart Center Leipzig / University Hospital for Cardiology, Cardiac Surgery and Pediatric Cardiology is part of the Helios Hospital Group. (2017-2018)
lung Bernard	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Novartis : Heart failure drugs (2017) - Boehringer Ingelheim : Anticoagulants (2017-2018) - Edwards Lifesciences : Heart valve prostheses (2017-2018)
Juni Peter	<p>1- Financial Declaration</p> <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Astra Zeneca : Anti-platelet Therapy (2017-2018) - Biotronik : Drug-eluting stents (2017-2018) - Biosensors International Group : Drug-eluting stents (2017-2018) - The Medicines Company : Thrombin inhibitors (2017-2018) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Peter Jüni has received research grants to the institution from Astra Zeneca, Biotronik, Biosensors International, Eli Lilly and The Medicines Company, and serves as unpaid member of the steering group of trials funded by Astra Zeneca, Biotronik, Biosensors, St. Jude Medical and The Medicines Company. (2017) - Peter Jüni serves as unpaid member of the steering group of trials funded by St. Jude Medical. (2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Katus Hugo	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Lixiana_NOAK (2017) - Astra Zeneca : Ticagrelor (2017) - Bayer Vital : Xarelto-NOAK (2017) - Daiichi Sankyo : Anticoagulants (2018) - Bayer Vital : Anticoagulants (2018) - Astrazeneca : Antiplatelet (2018) - Roche Diagnosticsker : Biomar (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - St Jude Medical : Biobank (2017) - Philips : MRT (2017) - Roche Diagnosticsarker : Biomarker (2018) - Daiichi Sankyo : Xarelto (2018) <p>2- Other Positions of Influence</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - President of the German Society of Cardiology (2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Landmesser Ulf	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott : Advisory Board fees (2017-2018) - Medicines Company : Advisory Board fees (2017-2018) - Amgen : Speaker fees (2017-2018) - Sanofi Aventis : Speaker fees (2017-2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer AG : Research Grant (2017-2018)
Leclercq Christophe	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Livanova : devices (2017) - Abbott : devices (2017-2018) - Boston Scientific : devices (2017-2018) - Medtronic : devices (2017-2018) - Biotronik : devices (2017-2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Biotronik : devices (2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Leclercq Christophe	<p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Biotronik : devices (2017)
Lettino Maddalena	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Antithrombotic agents, anticoagulants (2017) - Bristol Myers Squibb : Antithrombotic agents, anticoagulants (2017) - Amgen : Lipid lowering drugs (2017) - Pfizer : Anticoagulants (2017-2018) - Bayer Healthcare : Antithrombotic agents, anticoagulants (2017-2018) - Sanofi Aventis : Antithrombotic agents, anticoagulants, lipid lowering drugs (2017-2018) - Astra Zeneca : Antithrombotic agents, statins (2017-2018) - Daiichi Sankyo : Anticoagulants (2018)
Lewis Basil S	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Pfizer : Antithrombotics (2017-2018) - Merck Sharp & Dohme : Heart failure (2017-2018) - Astra Zeneca : Diabetes (2018) - CSL Behring : Lipidology, Secondary prevention (2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Lewis Basil S	<p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Novartis : Heart failure (2017) - Pfizer : Lipidology (2017) - Astrazeneca : Antithrombotics (2017-2018) - Astra Zeneca : Diabetes (2017-2018) - Pfizer : Diabetes (2017-2018) - Merck Sharp & Dohme : Heart failure (2017-2018) - Kowa : Lipidology (2017-2018) - Resverlogix : Lipidology. secondary prevention (2018)
Merkely Bela	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Sanofi Aventis : ACS (2017) - Medtronic : CRT course (2017-2018) - Abbott : CRT/ICD (2017-2018) - Biotronik : ICD/CRT (2017-2018) - Astra Zeneca : HF (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott : cardiac rhythm management (2017) - Medtronic : cardiac rhythm management (2017-2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Merkely Bela	- Boston Scientific : CRT (2017-2018)
Mueller Christian Eugen	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Servier : Antihypertensive (2017) - Siemens Healthcare : Diagnostics (2017) - Singulex : Diagnostics (2017) - Boehringer-Ingelheim : Antidiabetics (2017-2018) - Roche Diagnostics : Diagnostics (2017-2018) - Sanofi Aventis : Lipid lowering (2017-2018) - Indorsia : Antiplatelet therapy (2018) - Amgen : Lipid-lowering (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Beckman Coulter : Diagnostics (2017-2018) - OrthoClinical Diagnostics : Diagnostics (2017-2018) - Singulex : Diagnostics (2017-2018) - Abbott Laboratories : Diagnostics (2017-2018) - Roche Diagnostics : Diagnostics (2017-2018) - Siemens : Diagnostics (2017-2018) - Sphingotec : Diagnostics (2017-2018) - quidel : Diagnostics (2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Petersen Steffen Erhard	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Circle Cardiovascular Imaging, Inc : Cardiac MRI and CT analysis and reporting software (2017-2018) - Servier : Heart failure (2018) <p>2- Other Positions of Influence</p> <p>2.1 - Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: To reduce the burden of cardiovascular disease.</p> <ul style="list-style-type: none"> - Healthcare - IMAGING (2017) - Healthcare - IMAGING - I have option for shares for Circle Cardiovascular Imaging Inc. (2018)
Petronio Anna Sonia	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott : MitraClip (2017) - Boston Scientific : TAVI (2017) - Medtronic : TAVI (2017) - Boston Scientific : Percutaneous Aortic and Mitral treatment (2018) - Medtronic : Percutaneous Aortic and mitral treatment (2018) - Abbott : Percutaneous Mitral treatment (2018) <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boston Scientific : TAVI research (2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Priori Silvia Giuliana	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Boston Scientific : Cardiac device (2017-2018)</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Audentes Rx : Gene therapy (2017-2018)</p> <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY. - Takeda Pharmaceuticals : antiarrhythmic drugs (2017-2018)</p>
Richter Dimitrios	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY. - Novo-Nordisk : diabetes (2017) - Novartis : hypertension (2017) - Galenica : Lipids (2017) - Teva Pharmaceutical Industries : lipids, hypertension (2017) - Edwards Lifesciences : aortic stenosis (2017-2018) - Menarini : CAD- hypertension (2017-2018) - Unipharma : hypertension-thrombosis (2017-2018) - Abbott : lipids (2017-2018) - Amgen : lipids (2017-2018)</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Richter Dimitrios	<ul style="list-style-type: none"> - Sanofi Aventis : Lipids (2017-2018) - Lilly : Lipids (2017-2018) - Unilever : lipids (2017-2018) - Merck Sharp & Dohme : lipids (2017-2018) - Vianex : lipids (2017-2018) - Bayer Healthcare : Thrombosis (2017-2018) - Servier : LIPIDS (2018) - RAFARM : LIPIDS (2018) - ELPEN : LIPIDS-THROMBOSIS (2018) - Leo Pharma : THROMBOSIS (2018) - NovaGEM CYPRUS : THROMBOSIS (2018)
Roffi Marco	<p>1- Financial Declaration</p> <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Boston Scientific : Stents (2017-2018) - Medtronic : Stents (2017-2018) - Biotronik : stents (2017-2018) - Terumo Inc : stents (2017-2018) - Abbott Vascular : stents (2017-2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Shlyakhto Evgeny	<p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Krka Pharma : Arterial Hypertension (2017-2018) - Novartis : Arterial Hypertension, Heart Failure (2017-2018) - Merck Sharp & Dohme : Atherosclerosis (2017-2018) - Boehringer-Ingelheim : Dabigatran for Atrial Fibrillation (2017-2018) - Pfizer : General Cardiology (2017-2018)
Simpson Iain A	<p>Nothing to be declared (2018)</p> <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Member and Past President of the British Cardiovascular Society Member of the Management Board of the American College of Cardiology National Cardiovascular Data Registries (2017)
Sousa Uva Miguel	<p>Nothing to be declared (2017)</p> <p>1- Financial Declaration</p> <p>A - DIRECT PERSONAL PAYMENT AS IT APPLIES TO YOU AND YOUR SPOUSE/PARTNER OR ANY OTHER MEMBER OF YOUR HOUSEHOLD, OR ANY ENTITY CONTROLLED DIRECTLY OR INDIRECTLY BY ANY OF ABOVE PERSONS: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Abbott : Surgical Valves (2018)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Touyz Rhian	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Novartis : antihypertensive drugs (2017-2018) - Alnylam : antihypertensive drugs (2017-2018) <p>E - RESEARCH FUNDING (PERSONAL).</p> <ul style="list-style-type: none"> - British Heart Foundation : Hypertension research (2017-2018) - Medical Research Council, UK : Hypertension research (2017-2018) <p>2- Other Positions of Influence</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - American Heart Association International Society of Hypertension British Irish Hypertension Society (2017-2018)
Windecker Stephan	<p>1- Financial Declaration</p> <p>B - PAYMENT TO YOUR DEPARTMENT OR INSTITUTION OR ANY OTHER BODY LIKE AN ASSOCIATION OR SIMILAR FOR YOUR PERSONAL SERVICES: SPEAKER FEES, HONORARIA, CONSULTANCY, ADVISORY BOARD FEES, INVESTIGATOR, COMMITTEE MEMBER, ETC. FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - Bayer AG : General Cardiology (2017) - Abbott : Invasive Cardiology (2017) - Boston Scientific : Invasive Cardiology (2017) - Edwards Lifesciences : invasive Cardiology (2017) - CSL Behring : Invasive Cardiology (2018) - Polares Medical : Invasive Cardiology (2018) <p>D - RESEARCH FUNDING UNDER YOUR DIRECT/PERSONAL RESPONSIBILITY (TO DEPARTMENT OR INSTITUTION) FROM HEALTHCARE INDUSTRY.</p> <ul style="list-style-type: none"> - St. Jude Medical : General Cardiology (2017) - Amgen Inc. : General Cardiology (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2018.

Expert	Type of Relationship with Industry
Windecker Stephan	<ul style="list-style-type: none"> - Symetis SA : Invasive Cardiology (2017) - Biotronik : Invasive Cardiology (2017) - Terumo Inc : Invasive Cardiology (2017) - Abbott : General Cardiology (2017-2018) - Boston Scientific : General Cardiology (2017-2018) - Edwards Lifesciences : General Cardiology (2018) - Medtronic : General Cardiology (2018) - Biotronik : General Cardiology (2018) - Amgen Inc : General Cardiology (2018) - Bristol Myers Squibb : General Cardiology (2018) - Bayer AG : General Cardiology (2018) - Sinomed : General Cardiology (2018) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Deputy Editor JACC CV Interventions Section Editor Uptodate Board Member SITEM (Swiss Institute of Translational and Entrepreneur Medicine) Advisor ECRI (European Cardiovascular Research Institute) Course Director, PCR (2017-2018)